Insights

Expert John Buse, M.D., Ph.D., unpacks how hidden cortisol excess acts as a silent driver of treatment-resistant metabolic disease. The series reveals that roughly 25% of individuals with difficult-to-control type 2 diabetes unknowingly suffer from autonomous cortisol hypersecretion, a condition where the adrenal gland overproduces hormones that actively sabotage blood sugar and spike cardiovascular risk. Buse guides patients through the essential diagnostic steps and emerging cortisol-directed therapies, reframing a stubborn A1C not as a personal failure, but as a complex hormonal puzzle to be solved alongside a healthcare team.

Aboul-Fettouh clarifies the broad meaning of "alopecia" as a category, distinguishes alopecia areat as an autoimmune subtype, and addresses common patient misconceptions-including misplaced self-blame-that complicate early education and care.

An expert discusses how clinicians should approach the diagnosis of iron deficiency anemia, including appropriate ferritin thresholds, confirmatory laboratory testing, and the broader workup needed to identify the underlying cause.

Introduction to ISM with emphasis on evolving clinical perception, disease heterogeneity, and persistent unmet needs despite conventional symptomatic therapy.

In this discussion, April Armstrong, MD, MPH, explores current and emerging strategies for managing chronic spontaneous urticaria (CSU), emphasizing how updated guidelines, diagnostic efficiency, and new oral therapies such as remibrutinib are reshaping the treatment landscape. Drawing on pivotal data from the REMIX-1 and REMIX-2 trials and recent insights from Fall Clinical 2025, Armstrong discusses how clinicians can identify poor responders to antihistamines early, streamline escalation to biologic or small molecule therapy, and align care with patient preferences and access considerations. The series underscores a patient-centered, mechanism-driven approach to long-term CSU control and remission.

Dr. Lindsay Ackerman leads a comprehensive exploration of modern psoriasis care, from evolving biologic therapies and treatment selection to real-world data, emerging agents, and personalized precision medicine.

Cem Akin, MD, discusses how avapritinib, a selective KIT inhibitor, represents a significant advancement in treating indolent systemic mastocytosis by targeting the root cause of the disease and providing sustained symptom relief and quality of life improvements over long-term follow-up, while emphasizing the importance of careful patient selection and the need for ongoing research into combination therapies that might eventually lead to a cure.

A panelist discusses chronic spontaneous urticaria (CSU), highlighting its clinical features, emotional impact, current and emerging treatments—including omalizumab, dupilumab, remibrutinib, and barselolizumab—with an emphasis on shared decision-making, patient education, and the potential for future disease-modifying therapies offering sustained remission.

A panelist discusses how the DORA class of medications offers a novel approach to treating insomnia by selectively targeting orexin receptors to regulate sleep-wake cycles.

A panelist discusses how resistant hypertension remains a significant clinical challenge requiring accurate diagnosis, lifestyle and pharmacologic optimization, and emerging therapies such as aprocitentan to improve outcomes, especially in patients with comorbid conditions such as chronic kidney disease.

Raj Chovatiya, MD, PhD, discusses how chronic hand eczema presents significant diagnostic and treatment challenges due to its diverse etiologies, complex clinical presentations, and substantial impact on patients' daily functioning, and the limitations of current therapies, while highlighting promising emerging targeted treatments that may work across multiple subtypes.

Vivek Kaul, MD, discusses how effective colorectal cancer screening is crucial for preventing late-stage disease, highlightsing current guidelines and, available screening options, and talks about the importance of patient communication in the decision-making process.

Jean-Frederic Colombel, MD, provides a comprehensive overview of subcutaneous infliximab-dyyb injection for ulcerative colitis and Crohn's disease, analyzing clinical trial data, , discussing patient selection for this therapy, and evaluating its place in the evolving inflammatory bowel disease treatment landscape.

Wendy Wright, DNP, examines the impact of fibromyalgia on patients, evaluates existing treatment options, and explores the implications of long-term medication use for managing this chronic condition.

Dennis Marcus, MD, analyzes anti-VEGF utilization through surgical intervention in patients with neovascular AMD.

Shawn Kwatra, MD, provides clinical insights on how patient-reported incomes can improve quality of life in patients with atopic dermatitis.

Ruth Ann Vleugels, MD, MPH, MBA, provides comprehensive insights on the treatment of patients with atopic dermatitis, focusing on the role of JAK inhibitors in the treatment paradigm.

Christopher Bunick, MD, PhD, discusses the management of moderate to severe atopic dermatitis, including the use of systemic treatments, the importance of patient-reported outcomes in clinical trials and patient care, and advice for clinicians on developing comprehensive treatment plans.

Anjali Tiku Owens, MD, emphasizes the role of novel Cardiac Myosin inhibitors (CMI) in the treatment of patients with obstructive hypertrophic cardiomyopathy. She discusses recent clinical trial data, exciting ongoing clinical trials. and gives an in depth overview of how to safely prescribe the first approved CMI, mavacamten, for obstructive hypertrophic cardiomyopathy.

An expert retina specialist discusses typical challenging scenarios, including step edits and inadequate responses to anti-VEGF treatment, frequently encountered in managing patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), and outlines effective strategies to address these issues.

An expert in dermatology provides insight on the development of TYK2 inhibitors for the management of plaque psoriasis and reviews treatment approaches using oral systemic therapy for patients.

An expert in cardiology provides insight on the role of cardiac myosin inhibitors for the management of oHCM, highlighting key clinical trial data and findings as well as the role of the REMS program.

An expert in pain management reviews pharmacologic and nonpharmacologic treatment approaches to care management for patients with fibromyalgia.

Dr Stein Gold discusses how plaque psoriasis impacts a patient’s quality of life, even when smaller body surface areas are affected. She reviews data on systemic therapies from head-to-head trials, as well as recent data in patients with moderate plaque psoriasis.

An expert nephrologist discusses the burden and standard of care for patients with immunoglobulin A nephropathy (IgAN), new and emerging targeted immunomodulating therapies, and considerations for treatment.

An expert cardiologist discusses personalizing treatment of heart failure, highlighting guideline-directed medical therapy and clinical trial data for sacubitril/valsartan.

An expert rheumatologist reviews current treatment options in rheumatoid arthritis, focusing on tumor necrosis factor-α inhibitors (TNFi) and the molecular signature response classifier (MSRC) test.

Dr. Raj Chovatiya, MD, PhD, reviews recent FDA approval and how addition of new treatments can improve management of vitiligo going forward.